MIRA Pharmaceuticals (NASDAQ: MIRA) finishes Ketamir-2 Phase 1 dosing with encouraging safety

Rhea-AI Filing Summary

MIRA Pharmaceuticals reported completing dosing in its Phase 1 trial of Ketamir-2, a proprietary selective oral NMDA receptor modulator, in 56 healthy volunteers. The randomized, double-blind, placebo-controlled study included single and multiple ascending dose cohorts up to 600 mg.

Based on safety data reviewed to date, no serious adverse events, dose-limiting toxicities, or clinically significant dissociative or psychotomimetic effects typically associated with ketamine were observed. Final pharmacokinetic and safety analyses are underway.

The company intends to submit a Phase 2a proof-of-concept study to the FDA in the first half of 2026 for patients with moderate to severe chemotherapy-induced peripheral neuropathy, a condition with no FDA-approved therapies specifically indicated for it.

Insights

Biopharma clinical development analyst

MIRA advances Ketamir-2 with encouraging Phase 1 safety, targeting an area without approved CIPN therapies.

MIRA Pharmaceuticals has finished Phase 1 dosing of Ketamir-2 in 56 healthy volunteers, with no serious adverse events or dose-limiting toxicities reported at doses up to 600 mg. The absence of notable dissociative or psychotomimetic effects is important given ketamine’s typical side-effect profile.

The program now moves toward a Phase 2a proof-of-concept study in chemotherapy-induced peripheral neuropathy, where no therapies are specifically FDA-approved. This positions Ketamir-2 in an area of clear unmet need, but future value will hinge on whether the planned trial generates clinically meaningful safety and preliminary efficacy data.

false 0001904286 0001904286 2026-03-03 2026-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report: March 03, 2026

MIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41765		85-3354547
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

1200 Brickell Avenue, Suite 1950 #1183

Miami, Florida 33131

(Address of Principal Executive Offices)

(786) 432-9792

(Registrant’s telephone

number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		MIRA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”) announced that it has completed dosing in its Phase 1 clinical trial evaluating Ketamir-2, the Company’s proprietary selective oral NMDA receptor modulator, in healthy volunteers.

The randomized, double-blind, placebo-controlled study enrolled 56 healthy adult volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Based on safety data reviewed to date, no serious adverse events or dose-limiting toxicities have been reported at any dose level tested. In addition, no clinically significant dissociative or psychotomimetic effects typically associated with ketamine were observed. Database lock, unblinding, and final audited pharmacokinetic and safety analyses are underway.

The Phase 1 study was conducted at the Clinical Pharmacology Unit of Hadassah Medical Center in Jerusalem, Israel and was designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2. The SAD portion included four dose cohorts ranging from 50 mg to 600 mg (32 participants), and the MAD portion included three cohorts receiving daily oral doses of 150 mg, 300 mg, or 600 mg for five days (24 participants).

The Company intends to submit the Phase 2a clinical study and supporting documentation to the U.S. Food and Drug Administration under its active Investigational New Drug application in the first half of 2026. The planned proof-of-concept study is expected to enroll patients with moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) and is being designed to generate interpretable and clinically meaningful safety and preliminary efficacy data using validated neuropathic pain assessment tools and appropriate statistical powering.

Chemotherapy-induced peripheral neuropathy is a common and often dose-limiting complication of certain chemotherapy regimens and is characterized by persistent neuropathic pain, numbness, and sensory dysfunction. There are currently no FDA-approved therapies specifically indicated for CIPN, and management typically relies on off-label pharmacologic agents or intravenous ketamine.

The Company also stated that it plans to present Phase 1 data at an upcoming scientific meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MIRA PHARMACUTICALS, INC.
Dated: March 03, 2026	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

FAQ

What did MIRA Pharmaceuticals (MIRA) announce about its Ketamir-2 Phase 1 trial?

MIRA Pharmaceuticals announced completion of dosing in its Phase 1 trial of Ketamir-2 in 56 healthy volunteers. The study evaluated single and multiple ascending oral doses, focusing on safety, tolerability, and pharmacokinetics, and reported no serious adverse events or dose-limiting toxicities at any dose tested.

What were the key safety findings for Ketamir-2 reported by MIRA Pharmaceuticals?

The company reported no serious adverse events or dose-limiting toxicities at any tested dose of Ketamir-2. It also noted no clinically significant dissociative or psychotomimetic effects typically associated with ketamine, which may be important for tolerability. Final pharmacokinetic and safety analyses are still underway following database lock and unblinding.

How was the Ketamir-2 Phase 1 study for MIRA (MIRA) designed and dosed?

The Phase 1 trial was randomized, double-blind, and placebo-controlled, conducted in healthy adults. It included single ascending dose cohorts from 50 mg to 600 mg and multiple ascending dose cohorts of 150 mg, 300 mg, and 600 mg given daily for five days, totaling 56 participants overall across both parts.

What are MIRA Pharmaceuticals’ next clinical plans for Ketamir-2?

MIRA intends to submit a Phase 2a clinical study to the U.S. FDA in the first half of 2026 under its active IND. The planned proof-of-concept trial will enroll patients with moderate to severe chemotherapy-induced peripheral neuropathy and aims to generate interpretable safety and preliminary efficacy data using validated pain endpoints.

Why is chemotherapy-induced peripheral neuropathy (CIPN) a focus for MIRA’s Ketamir-2 program?

Chemotherapy-induced peripheral neuropathy is a common, often dose-limiting complication of certain chemotherapies, characterized by neuropathic pain, numbness, and sensory dysfunction. The filing notes there are currently no FDA-approved therapies specifically indicated for CIPN, and management often relies on off-label agents or intravenous ketamine, highlighting unmet medical need.

Where was the Ketamir-2 Phase 1 trial for MIRA Pharmaceuticals conducted?

The Phase 1 Ketamir-2 study was conducted at the Clinical Pharmacology Unit of Hadassah Medical Center in Jerusalem, Israel. The trial evaluated oral administration of Ketamir-2 in healthy volunteers and was designed to assess safety, tolerability, and pharmacokinetics under randomized, double-blind, placebo-controlled conditions.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB